Asthma is a disease which is increasing in frequency and represent over 50% of the total costs associated with severity despite the incontestable advances in the underasthma. No satisfactory alternative therapy is currently standing of its physiology and treatment. New therapeutic available. In this regard, a variety of gene-based strategies strategies are therefore required and at the time when a have recently been proposed for inflammatory and new treatment, that of gene therapy, is giving hope for the immunologic disorders. It is thus the purpose of this review treatment of so far incurable illnesses, it would seem to us to consider its application to asthma therapy, although to be useful to discuss the possible use of this treatment there are very few published works that directly bear on in severe asthma and in particular in the case of the most gene therapy linked to asthma. After a brief outline of the severe asthmatic patients requiring continuous oral steroid epidemiology of asthma, its genetics and the available anitreatment (referred to as steroid-dependent). These mal models, we will focus on its immunopathology slanting patients are those who require particular medical attention, the discussion towards the possibility of a gene-based they often need to be admitted to hospital and they treatment.
Introduction
costs of asthma have occurred despite great advances in Epidemiological surveys performed in occidental counthe understanding of the physiological mechanisms of tries suggest that the prevalence of asthma is between 6-the disease and of better medical treatment. The major 12% in children and 6-8% in adults. The prevalence and advance over the last few years has been the understandthe severity of this disease have continually increased ing of asthma as an inflammatory disease and the use since 1960. 1 In the USA, the prevalence of asthma has of corticosteroids in its treatment. Whilst ␤2-agonists and increased by approximately 50% over the last 10 years, 1 inhaled corticosteroids are able to control the disease in particularly in the lower socio-economic classes (Blacks the majority of patients, this does not hold for all cases, and Hispanics). The number of American asthmatics has in particular those patients who require in addition daily thus been estimated at over 12 million people. In doses of oral corticosteroids. New therapeutic strategies addition, the number of hospitalizations for asthma has must therefore be devised for these patients. In this increased in virtually all occidental countries; this is not regard, a variety of gene-based strategies have recently simply due to an increase in diagnosis, but reflects a real been proposed for inflammatory and immunologic disincrease in the morbidity of the disease 2 and in some orders. It is thus the purpose of this review to consider countries there has also been a rise in the mortality.
2, 3 In its application to asthma therapy. In order to define a the USA, the mortality due to asthma has increased from new therapeutic strategy for asthma, we must first 0.8/100 000 individuals in 1977 (ie 1674 deaths) to explore the present understanding of the genetics and the 1.6/100 000 individuals (ie 3955 deaths) in 1986, and is pathophysiology of this disease. After reviewing the continuing to rise with 4580 deaths being reported in available data, we shall go on to discuss the patients with 1988. 4, 5 The socio-professional impact of asthma is also severe asthma who may be those targeted to benefit first important, responsible for the loss of 5 million working from the treatment. Before considering the different vecdays per year in France and approximately 25% of all tors and strategies which can be used for gene transfer, school absenteeism. Finally, the costs associated with animal models of asthma which are essential for the asthma should be emphasized: asthma represents 1% of evaluation of any treatment and particularly for gene all medical costs in developed countries accounting for therapy will be discussed. It must be noted that this 6.2 billion dollars per year in the USA in the early 1990s review is not entirely theoretical since, at present, there (as against 1 billion dollars in 1975). 6 In France, asthma are some data to support the use of this treatment in costs the country approximately 8 billion French Francs asthma. per year. (on chromosome 14), 9 the gene for interleukin (IL)-4 (on chromosome 5q), 10 and the gene for the ␤-chain of the this area. Is there an abnormality in the presentation of high affinity receptor for IgE (on chromosome 11q)
antigens? Is the origin due to a deregulation in the synrespectively. 11 Such molecular genetic studies have thesis of mediators (an upregulation in the activity of the already made advances in this area. However, very little enzymes involved or a decrease in the synthesis of downgenetic information is currently available in the case of regulators)? Is there an initial abnormality in the traffic severe asthma. Polymorphisms in certain genes (eg ␤ or cellular co-operation, possibly involving chemoattracadrenergic receptor coding sequences and IL-4 promoter tants or their receptors, adhesion molecules and stimusequences) have been found in severe asthma. 12, 13 Howlatory cytokines? Although at present we are unable to ever a familial link with the severity of asthma has yet answer these questions, we can confirm that the bronto be fully established. The development and the continuchial epithelium is both the site of inflammation and itself ation of such studies together with the human genome plays an important role in the inflammatory process, and program will allow us to envisage a future with research should therefore be the primary target for the treatment into the genetics of asthma and allergies in terms of funof asthma. Following on from the detailed study of some damental research, of prevention and of new therapeutic of the mechanisms underlying the pathophysiology of strategies (including gene therapy).
asthma, various strategies designed to investigate the feasibility of therapeutic approaches involving gene therPathophysiology of asthma apy will be discussed below. Under normal conditions, the airways are covered with a multi-stratified, ciliated, cylindrical epithelium. Anatomo-pathological studies performed on patients who Which asthmatic patients could benefit from have died from status asthmaticus, and in vivo studies, this treatment?
have demonstrated the importance of the inflammatory reaction.
14 No one cell type or mediator is implicated in Therapeutic advances over the past two decades have enabled us to obtain satisfactory results both clinically this inflammatory reaction but rather a network of cells and mediators is involved. [14] [15] [16] Morphologically speakand functionally in the majority of patients. Corticosteroids are the most effective treatment for asthma and reping, the airways of an asthmatic are abnormal (Figure 1 ). Histological lesions are more clearly visible in the upper resent the only therapy which can significantly reduce bronchial inflammation. Although these drugs are generlayers, thus the epithelium is the region with the most lesions. None of the lesions observed, whether in the epially administered by inhalation, long-term oral administration is sometimes required in order to control the disthelium, the chorion or the submucosa is specific to asthma but their presence is indicative of this disease. ease (steroid-dependent patients). The small group of patients who require oral corticosteroids is very heteroThese abnormalities are localized and inflammatory in nature, being both lesional (edema, epithelial desquageneous, both clinically and functionally; 17 some are stable and have a quasi-normal lung function with a mation and inflammatory cell infiltration -principally mast cells, eosinophils, lymphocytes and activated cells corticosteroid dose of around 10 mg per day, while others remain unstable despite taking much higher doses of of the monocyte/macrophage lineage) and reconstructive (hyperplasia of goblet cells, hypertrophy/hyperplasia of these drugs. Particular attention is required due to the potential side-effects of this treatment (the possibility of the glands and smooth muscle, subepithelial fibrosis, myofibroblast hyperplasia and activation). Despite extenstunted growth in children, steroid-induced osteoporosis, cutaneous fragility, an increase in the risk of infections, sive studies of cells and associated mediators, the underlying mechanisms of asthma remain poorly understood.
cataracts and diabetes) and to the associated severe underlying bronchial inflammation (with increased risk To this detailed anatomo-pathophysiological perspective we should add a mechanistic dimension which, at of hospitalization and death). The corticosteroids appear to be less effective for the bronchial inflammation of present, is incomplete due to the lack of knowledge in steroid-dependent patients although the reasons for this would seem that the most severe steroid-dependent patients and in particular those who are steroid-resistant are ill-defined. Finally, there is an even smaller subgroup of patients who are completely resistant to corticosteroids should be considered the primary target for such therapeutic intervention. (steroid-resistant patients). In both cases one can speak of 'steroid-resistance' with certain differences in the degree of resistance. No epidemiological data are availAre the available animal models sufficient? able but these patients represent 0.1 to 0.01% of all asthmatic subjects. 18 Numerous corticosteroid-sparing agents One cannot talk about therapy in any form, and particularly gene therapy, without recourse to animal studies have been proposed but without major success irrespective of the particular drug tested, and severe side-effects on the feasibility and toxicity of the treatment. A proper model of asthma must not only reflect certain physiologihave been reported for some of them (methotrexate, chloroquine, dapsone, troleandomycin or cyclosporin). 19 An cal signs (bronchial hyperreactivity, increase in airway resistance) and clinical symptoms, but should also reproalternative approach is therefore needed and will likely be based on the understanding of the mechanisms underduce the biological situation (synthesis of IgE, cellular activation and synthesis of mediators) and most of the lying steroid-resistance.
Many hypotheses have been put forward to explain histological signs of the disease (edema of the mucosa, infiltration of activated cells into the bronchi, and epithis resistance but there is no consensus, and suggestions range from pharmacological explanations (increase in thelial shedding). In the case of cystic fibrosis for example, studies on the feasibility and on the toxicity of plasma clearance of cortisol, variations in the kinetics of corticosteroids) to cellular-based proposals (abnorthe transfer of the CFTR (cystic fibrosis transmembrane conductance regulator) in healthy animals were sufficient malities in monocyte and/or lymphocyte function) [20] [21] [22] [23] or molecular-based proposals (abnormalities in the corticoto allow the initiation of protocols involving gene transfer in human adults suffering from this lethal disease. steroid receptor (GR) or GR binding to its ligand and its DNA target). [24] [25] [26] [27] Although pharmacological theories Despite the lack of animal models at that time, and due to the severe prognosis of cystic fibrosis and the wellremain controversial and for some are largely based on the severity of the disease, 18 cellular-based hypotheses established understanding of its pathophysiology, these preclinical studies permitted the first gene therapy trials have to date no defined molecular basis. Nevertheless, it has repeatedly been stated that in steroid-resistant asthonly 4 years after the discovery of the CFTR gene. 30 In asthma, current models do not in all cases reflect the full matics there is a decrease in the effects of corticosteroids on the inhibition of phytohemaglutinin-induced blood range of the characteristics of asthma, but are nevertheless sufficient to allow animal studies on the feasibility monocyte maturation, on the inhibition of cytokine liberation from peripheral blood monocytes, on the decrease and toxicity of such therapy. The principal animal models of asthma are models of induced allergy (following sensiin activated eosinophils and T lymphocytes in bronchoalveolar lavage fluid and on the cutaneous blanching tization with composites of high molecular weight, principally ovalbumin) involving increased resistance in the when corticosteroids are applied topically. 18, 20, 22, 23 The increased inflammation observed in steroid-resistant airways of the animals used with early and/or late phase reactions. Most models reflect transitory reactions which patients is reflected functionally by an increase in nonspecific bronchial hyperreactivity 21 and biologically by T mimic acute allergic but not chronic asthma, except for some very recent studies described below. Relatively few lymphocytes in peripheral blood and broncho-alveolar lavage fluid which express increased levels of membrane animals (Basenji greyhounds, some monkeys and ponies) develop natural allergies and can develop persistent resmarkers of inflammation (CD25 and HLA-DR or human leukocyte antigen DR) and messenger RNA for inflampiratory allergic reactions with the appearance of metachromatic cells and lymphocytes in the broncho-alveolar matory cytokines (IL-2 and IL-4). 28 Studies so far published reveal two types of abnormalities of the GR in sterlavage fluid. 31 To this end, numerous animal species have however been utilized in the development of models of oid-resistant asthma: a decrease in the affinity for the hormone 24, 25 and a diminution in the numbers of recepasthma including mice, rats, guinea-pigs, hamsters, rabbits, dogs, horses, sheep, pigs and monkeys. 31 tors which bind with high affinity to the DNA 26 and this could be explained by an increase in AP-1 (activator proIn fact, of all the models which have been proposed as being potentially useful for the study of the pathophysioltein-1)/GR complexes. 27 What are the molecular bases of these abnormalities? The primary structure of the GR ogy of asthma, the mouse seems to be particularly useful due to the preponderance of immunological mechanisms does not seem to be a major cause since in six patients with steroid-resistance, chemical mutation analysis of the in this disease. It is a small laboratory animal which can be easily handled and for which all the immunological complementary DNA did not show any mutation. 29 The presence of high concentrations of pro-inflammatory tools are commercially available. Mice sensitized to ovalbumin and challenged with ovalbumin aerosols [32] [33] [34] cytokines is often cited as being a major cause, particularly IL-2 and IL-4. A combination of the two cytokines develop both an immediate IgE-dependent reaction and a late phase reaction involving an increase in specific IgE, has been found to induce and maintain a low affinity of the GR in T lymphocytes of both steroid-resistant subjects an immediate cutaneous response to ovalbumin, 32 increased numbers of eosinophils in the peripheral circuand in healthy volunteers ex vivo. 24 IFN-␥ negates the effect of the IL-2/IL-4 combination probably by favoring lation, decreased cell numbers in the bone marrow, increased numbers of activated cells (principally eosinothe differentiation of Th1 rather than Th2 cells. 24 Moreover, these patients have increased the number of bronphils and T cells) in broncho-alveolar lavage fluid (with a maximum on the third day with persistence until the cho-alveolar cells expressing IL-2 and IL-4 mRNA, suggesting that this phenomenon may happen in vivo. 28 sixth day), epithelial shedding, edema of the bronchial mucosa, significant infiltration of eosinophils and Thus, from a perspective of gene therapy for asthma, it lymphocytes into the bronchi, bronchioles and alveoli, given the importance of the role of lymphocytes in the pathophysiology of asthma, ex vivo gene therapy should plugging of the airway lumen as a consequence of goblet cell hyperplasia in terminal bronchioles and larger airalso be considered with isolation, purification, genetic modification in vitro and reinfection of lymphocytes ways, and interestingly also a deposition of fibrotic material beneath the basement membrane of the airway which when they relocalise to the bronchial epithelium could beneficially modulate the local immune response. epithelium after repeated challenges. 34 As in man, the influx of eosinophils is under the control of CD4 + Th2 Moreover, understanding the role played by cells of the monocyte-macrophage lineage in presenting antigens to lymphocytes [35] [36] [37] and mast cells 38 which secrete chemotactic and activating cytokines such as granulocytelymphocytes and with the easy access to alveolar macrophages by broncho-alveolar lavage and their privileged macrophage colony-stimulating factor (GM-CSF), IL-3 and IL-5. 33 Thus, many of the characteristic features of position in contact with the bronchial epithelium, a strategy targeting alveolar macrophages could also be human atopic asthma are seen in the antigen-challenged mouse model. Moreover, recent data 34 suggest that mulapplied. Thus, it is not impossible to envisage ex vivo gene therapy in asthma targeting alveolar macrophages tiple challenges are also able to reproduce the commonly observed histologic feature of human chronic asthma (ie which could be transfected in vitro and then reintroduced into the body to allow the in situ liberation of the recomsubepithelial fibrosis). The ability to use macaque monkeys (Macaca fascicularis) which can be sensitized to Ascaris binant protein, product of the therapeutic gene. suum is of great interest for the development of gene therapy in asthma since the use of primates before gene ther-
The genes of interest As we have already said, gene therapy in asthma cannot apy in humans is indispensable. These animals generally have high numbers of eosinophils in their bronchorely on data from molecular genetic studies since the gene(s) involved still remain to be determined. Therefore, alveolar lavage fluid. 39 After challenge with allergen aerosols, they develop both an allergic-type acute respirgene therapy such as it is currently under trial in monogenetic diseases like cystic fibrosis cannot be envisaged. atory reaction and a late phase reaction characterized by nonspecific bronchial hyperreactivity and an increase in However, as a result of detailed studies on certain established mechanisms underlying the pathophysiology of airways resistance. A massive influx of eosinophils into the alveoli is observed 39 together with epithelial shedasthma, we can suggest several possible lines of research. Whilst to replace a deficient gene is a 'simple task' in the ding 40 and the induction of the expression of the intracellular adhesion molecule (ICAM)-1 (CD54) on epithelial realms of gene therapy, to block the expression of this or that inflammatory or immunoregulatory protein necessiand vascular cells. 39, 40 Thus, available small and large animal models of asthma appear sufficient to evaluate new tates sophisticated gene therapy techniques, such as for example soluble receptors, negative dominants, ribotherapeutic strategies, including gene therapy. It should be noted however that, as yet, no animal model exists of somes, single chain intracellular antibodies or antisense oligonucleotides. In asthma, no protein is truly repressed, severe and/or steroid-dependent asthma.
but rather there is a hypersecretion. However, the discovery of immunomodulating cytokines which may be What strategies could be envisaged for anti-inflammatory, such as interferon (IFN)-␥, IL-10 and gene transfer in asthma?
IL-12, opens new perspectives which will be elaborated on below. Vector approaches Many systems for gene transfer are currently available.
Action on the infiltration and activation of eosinophils: The targeting of eosinophils is a possible therapeutic strategy Their major advantages and disadvantages are outlined elsewhere. We shall not explore this subject in greater under consideration. These cells infiltrate the bronchial mucosa of asthmatic subjects whether they are allergic or depth and instead refer our readers to the excellent reviews available. [41] [42] [43] We should however, draw attennot, and are often degranulated and activated in terms of liberation of cytotoxic granule-derived proteins (such tion to the side-effects and particularly the inflammation induced by these vectors which must be taken into as eosinophil cationic protein (ECP) and major basic protein (MBP) ) and bronchoconstrictive lipid-derived account in diseases such as asthma where the major feature is bronchial inflammation. If we accept that the epimediators such as platelet-activating factor (PAF) and leukotriene (LT) C4. 44 In addition, the numbers of eosinothelium is the target site in asthma (the most efficacious medications being administered by aerosol), the precise phils and their corresponding mediators are increased following allergic provocation. 45 The eosinophilic infilcell that should be targeted remains unclear (Figure 1) . Vectors have different efficacies depending upon the cell trate is correlated with the severity 44 of the disease and sometimes with the level of bronchial hyperreactivity. type involved. Thus, while adenovirus vectors may be employed for airway epithelial cells, they are much less This infiltration is less marked or absent in asthmatic patients treated with inhaled or oral corticosteroids. The effective for gene transfer to lymphocytes. Differentiated peripheral blood lymphocytes are a cell type which increased number of eosinophils could be due to an influx of cells from the peripheral circulation or to an resists transfection and thus new strategies have to be evaluated. However, these cells could potentially be tarincrease in their survival time. The recruitment of eosinophils from the blood involves a number of different geted via epithelial cells by transferring to this latter cell type the gene for a protein secreted into the local processes. 46 The initial adhesion and the passage across the endothelium brings into play a cascade of various microenvironment and known to modulate lymphocyte function. The bronchial site of this inflammation means adhesion molecules (Figure 2 ). The migration through the bronchial epithelium is probably under the command of that full advantage can be taken of current in vivo technology with aerosols of the therapeutic gene(s); but, chemo-attractant factors such as GM-CSF, C5a, PAF, IL-eosinophil infiltration. The study of bronchial biopsies in asthmatics has shown an increased expression of Mac-1 (CD11b/CD18), LFA-1, VLA-4, ICAM-1, E-selectin (ELAM-1, endothelial leukocyte adhesion molecule-1 or CD62E) and vascular cell adhesion molecule (VCAM)-1 (CD106). 56 Many of these molecules are common to all granulocytes, while others such as VLA-4 are only expressed on eosinophils. 57 Other authors have reported an increase in the levels of soluble E-selectin 58 and soluble ICAM-1 59 in the broncho-alveolar lavage fluid of asthmatic patients 18 h after allergen challenge; an increase in serum E-selectin and ICAM-1 values in acute asthma 60 and an increase in the expression of these two adhesion molecules in the bronchial microvasculature 6 h after endobronchial allergen challenge. 61 Some animal studies in the sheep 53 and in ovalbumin sensitized 
ICAM-1 antibodies in monkeys diminishes the supas eosinophil cationic protein (ECP) and eosinophil peroxidase (EPO).
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plementary influx of eosinophils and the associated nonspecific bronchial hyperreactivity 39 but, however, has no effect on the basal infiltration. 40 These studies underline 3, IL-5, monocyte chemo-attractant protein (MCP)-3, macrophage inflammatory protein (MIP)-1␣, RANTES the important but not exclusive role of adhesion molecules in the phenomena surrounding cellular actiand IL-8 which are all chemotactic for eosinophils. 47 GM-CSF for example, has several properties which attract, vation. 64 Animal studies have also demonstrated the feasibility of targeting pro-inflammatory cytokines which activate and prolong the survival of eosinophils. It is synthesized to a greater extent in the mucosa of asthmatic are able to activate endothelial cells and induce the expression of adhesion molecules. Thus, the use of a subjects and is found in higher levels in the bronchoalveolar lavage fluid and occasionally in peripheral receptor antagonist for IL-1 in the guinea pig 65 and for the soluble receptor for tumor necrosis factor (TNF) in blood. The level of expression is correlated with the number of eosinophils, the degree of bronchial hyperreactivthe mouse 47 has resulted in both cases in a decrease in the eosinophilic infiltrate. Thus, the block of cellular ity and is decreased following oral corticosteroids therapy. 48 IL-5 exhibits the same properties on the eosinophil. recruitment into the bronchial epithelium by targeting chemo-attractants, their receptors, adhesion molecules Using in situ hybridization techniques and cells obtained from broncho-alveolar lavage and bronchial biopsies, it and the cytokines which induce the expression of these factors is a possible therapeutic strategy. The use of a has been shown that the number of cells transcribing the gene for IL-5 is increased in asthmatic subjects when monoclonal antibody in man may induce a rapid immune response against these antibodies; however, the techcompared with normal subjects and that this effect is correlated with the numbers of eosinophils present, the niques of gene transfer represent a possible alternative. Deactivation of the eosinophils already present in the airextent of obstruction and degree of bronchial hyperreactivity. 49, 50 The feasibility of a therapy which appears to ways is another therapeutic strategy to look at. As a matter of fact, the targeting of adhesion molecules involves oppose the influx of eosinophils (again the major cause of lesions and of the increase in bronchial this objective and animal studies have already proved its potential usefulness. 64 Thus, the administration of antihyperreactivity) via the use of antibodies directed against cytokines and adhesion molecules has been demon-VLA-4 antibodies to sensitized sheep has been shown to diminish the release of PAF-induced eosinophil peroxistrated in the mouse, 33 guinea pig, 51 rat, 52 sheep, 53 and monkey 54 models of asthma. The injection of anti-IL-5 dase (EPO) in vitro. 53 The binding of eosinophils to fibronectin via VLA-4 induces a secretion of LTC4, ECP and antibodies into mouse 33 and the monkey 54 models reduces both the numbers of eosinophils and the associa-EPO 57 ( Figure 2 ). Lefort et al 66 have recently shown that neutralization of endogenously secreted MBP utilizing a ted bronchial hyperreactivity. The absence of an eosinophilic infiltration and of increased bronchial hyperreacspecific antiserum, prevented antigen-induced bronchial hyperreactivity in ovalbumin-sensitized guinea pigs, tivity in mice sensitized to ovalbumin but deficient in IL-4 37, 55 gives rise to a different target for the development without affecting the number of broncho-alveolar eosinophils. To target directly the enzymes involved in the synof new treatments in asthma. However, the use of anti-IL-4 antibodies does not diminish the eosinophilic infilthesis of lipid mediators, granular proteins, cytokines which activate eosinophils and their receptors is another tration except when administered during the sensitization phase. In addition, animal studies using blocking strategy one might consider. In fact, numerous illnesses are associated with an infiltration of eosinophils into the antibodies have demonstrated the role of adhesion molecules such as ICAM-1, 39 very late activation antigen lungs (eg drug allergies, eosinophil-associated pneumonia and histocytosis X) but are not accompanied by (VLA)-4 (␣4␤1, CD49d/CD29), 51, 52 and lymphocyte function associated antigen (LFA)-1 (CD11a/CD18) 52 in this asthma which not only involves recruitment of these cells 512 but also an activation signal. The basis of this strategy tration of other inflammatory cells, particularly of eosinophils, as we have discussed above and we shall see was first outlined by White et al. 67 By chemically blocking human eosinophil phospholipase A2 (PLA2), these further examples. This action would also diminish the production of IgE. Two signals are necessary for the synauthors completely inhibited the liberation of EPO as well as blocking the arachidonic acid breakdown paththesis of IgE: 69 IL-4 (and as shown more recently IL-13) which induces the isotype switch and the interaction way. An action on the enzymes of the arachidonic acid cascade is already an objective of classical pharmacologibetween the T cell receptor-CD3 complexes and the HLA-DR complex of B cells. This interaction can equally cal therapies (with, for example the appearance of anti-5-lipoxygenases on the market). The enzyme of interest occur via the intermediary of the CD40 ligand with CD40. IFN-␥, IFN-␣, transforming growth factor (TGF)-␤, IL-8 which could be inhibited by antisense gene therapy would be the cytosolic PLA2, which is the rate-limiting and IL-12 oppose the action of IL-4 whilst IL-6 and TGF-␣ stimulate IgE synthesis. enzyme for arachidonic acid production from membrane phospholipids. 68 An action on enzymes which are Let us now review some of the therapeutic interventions already attempted at the IgE synthesis level. The involved in the later stages of the arachidonic acid cascade would likely be less efficient and would not allow use of IL-4 receptors inhibits the synthesis of IL-4-dependent IgE production. 70 Replacing tyrosine at position 124 a concomitant action on the granular protein pathway described above.
of IL-4 with aspartic acid gives rise to a mutated form of the IL-4 protein. This Tyr-Asp-IL-4 mutant is capable of binding to the IL-4 receptor but incapable of activating Action on the infiltration and activation of T lymphocytes: Targeting of T lymphocytes is another therapeutic possiit. Using a SCID mouse model, it has been demonstrated both in vitro and in vivo that Tyr-Asp-IL-4 mutant is able bility. In asthmatics, there is an increased number of activated T cells, in the lamina propria and occasionally the to inhibit the IL-4 or IL-13-induced synthesis of IgE.
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Injection of IFN-␥ into human subjects with hyper-IgE epithelium. Many express membrane markers of activation such as CD25, the IL-2 receptor or HLA-DR. 15, 16 syndrome, atopic eczema, allergic rhinitis or steroiddependent asthma has no significant effect on serum levAs for eosinophils, the degree of infiltration is variable from one subject to another. The infiltration is mainly els of total or specific IgE, although in some cases a reduction in the spontaneous production of IgE by monocomposed of T helper cells (CD4 + ) which are often said to be equivalent to the mouse Th2 lineage (demonstrated cytes of treated patients has been reported. [72] [73] [74] [75] A clinical improvement has been observed in patients with atopic using in situ hybridization by the presence of messenger RNA for IL-4 and IL-5 in broncho-alveolar lavage cells 50 eczema who do not respond to conventional treatments. Side-effects are notably nausea, vomiting, headaches, and bronchial biopsies). 49 These cells synthesize, at least in vitro IL-3, IL-4, IL-5, IL-6 and GM-CSF but not IFN-␥ fever, fatigue and occasionally a mild neutropenia. These effects are not seen when IFN-␥ is administered by aeroor IL-2 ( Figure 3 ). Thus, they control both the synthesis of IgE, chemotactism, proliferation and/or differentiation sol 76,77 underlining the advisability of local administration. When this cytokine was administered by aerosol and/or local activation ( Figure 1 ) and possibly govern other cell types involved in asthma such as eosinophils to ovalbumin-sensitized mice, no inhibition of the IgE response was seen unless the cytokine was given simul-(IL-5, IL-3, GM-CSF), mast cells and basophils (IL-1, IL-3, IL-4, IL-5, IL-10, GM-CSF) and cells of the monocytetaneously with, or better, 3 days before allergen administration. 32 Even this local administration exposes the submacrophage lineage (GM-CSF, IL-4, IFN-␥). This cellular infiltration is correlated with the number of eosinophils ject to certain theoretical risks involving localized activation of the bronchial epithelium with increased perpresent, the level of bronchial obstruction and the bronchial hyperreactivity. 50 Inhaled corticosteroids sigmeability of the epithelial barrier and induction of increased expression of HLA-DR, ICAM-1 and nitric nificantly decrease the numbers of T cells and other inflammatory cells, suggesting that T cells are likely to oxide synthase. A recent study involving five asthmatic subjects and five controls showed that 3 weeks of treatbe the major target for these drugs.
An action on T cells would first of all reduce the infilment with inhaled IFN-␥ was well-tolerated but did not affect the respiratory parameters measured (bronchial hyperreactivity to methacholine, FEV1, morning peak flow) or the expression of HLA-DR or ICAM-1 on the bronchial biopsies obtained. 77 The possible modulation of the IgE response was not investigated in this study. A different strategy could be to utilize soluble forms of CD40 which, by inhibiting interactions between T and B lymphocytes, would result in the inhibition of IgE production. 78 In consequence, modulation of IgE-synthesis by acting on IL-4 whilst possible is not simple, B lymphocytes having apparently no further need for IL-4 once they are committed to IgE production. 69 As the immune response which leads to the synthesis of IgE takes place in the pulmonary lymphatic ganglions, the problem of targeting these cells arises. All therapy which has as its aim the blockage of IL-4 either directly (antisense therapy) or indirectly (involving the use of immunomodulatory cytokines such as IFN-␥ or IL-12) will only inter- vene in new sensitizations and have little or no effect on already established responses. The production of IgE liferation of these cells and inhibiting the development of Th2-lymphocytes. 86 This action is due in part to the could also be modified by the removal of B lymphocytes which express IgE on their surface. The feasibility of such induction, in synergy with IL-2, of the synthesis of IFN-␥ and stimulation of natural killer (NK) cells. The feasia strategy has recently been described by Lustgarten and Eshhar 79 who transfected T lymphocyte cell lines with a bility of this form of therapy has recently been demonstrated in Balb/c mice which were sensitized to ragweed chimeric T cell receptor containing the variable region of a nonanaphylactic anti-IgE antibody directed against the pollens. 87 Intraperitoneal injections of IL-12 for several successive days before intratracheal challenge with the binding zone of IgE with the high affinity receptor. These cells were thus capable of being specifically activated and sensitizing allergen decreased the serum levels of specific IgE, the levels of IL-4 in broncho-alveolar lavage fluid to synthesize IL-2 when placed in contact with B lymphocytes expressing IgE on their membrane surface. In this and the numbers of cells in this fluid which expressed the mRNA for the Th2 cytokines IL-4, IL-5 and IL-10. The way, ex vivo manipulation of peripheral blood T lymphocytes would allow the continuous and long-lasting elimlevels of IFN-␥, the numbers of cells expressing mRNA for IFN-␥ and the numbers of eosinophils in the lavage ination of IgE-producing cells without risk of anaphylaxis as a result of mast cell activation. It would also overcome fluid were also clearly decreased. 87 However, it would be interesting to ascertain the effect of such a treatment the problem of the incomplete and short-lived efficacy which arises if one tries to remove IgE-producing B lymadministered after and not during the sensitization phase. IL-10 is another interesting immunomodulating phocytes by injection of anti-IgE antibodies whether these antibodies be used on their own or coupled to ricin candidate due to its inhibitory effects on the functions of monocytes/macrophages, lymphocytes and eosinophils. toxin A.
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The last and not the least strategy aimed at reducing IL-10 is produced by Th0 and Th2 cells, B-lymphocytes, monocytes/macrophages and bronchial epithelial IgE synthesis is specific immunotherapy. Although classic immunotherapy with allergen extracts downcells. 88, 89 Moreover, IL-10 activates both B lymphocytes and mast cells in terms of proliferation and of viability. 88 regulates the T cell responses and has beneficial effects in highly selected asthmatic patients, more efficient and This cytokine is a powerful immunosuppressor of monocyte-macrophage and dendritic cell functions (including safe methods are being sought. 80 Gene transfer technology (ie DNA vaccines) has recently been applied to the synthesis of cytokines, the genesis of oxygen free radicals and antigen presentation). 88 This latter effect is the allergen immunotherapy as it is being evaluated in neoplastic and mainly infectious diseases. 81 Balb/c mice means by which IL-10 has been shown to be an inhibitor of IL-4-induced IgE production. 90 IL-10 inhibits the proimmunized intradermally with a plasmid DNA encoding the Escherichia coli beta-galactosidase (␤-gal) mounted a liferation of Th1 lymphocytes and neutrophils and the synthesis of their cytokines (IL-2, IFN-␥, IL-3, TNF, GMspecific Th1 response whereas ␤-gal protein immunization induced a Th2 response to the same antigen.
CSF)
. 88 Finally, IL-10 inhibits eosinophil survival and cytokine production (GM-CSF, TNF-␣, IL-8). 91 Wooley et Plasmid ␤-gal DNA intradermal injections into ␤-gal-sensitized mice caused a 66-75% reduction of the specific IgE al 92 have demonstrated that intratracheal injection of IL-10 several minutes before allergenic provocation in ovallevel. Intramuscular injections of rats with a plasmid DNA encoding a house dust mite allergen has also been bumin-sensitized rats significantly inhibits the late phase response, the influx of eosinophils and lymphocytes into shown to prevent aerosolized allergen-induced induction of IgE synthesis, histamine release in broncho-alveolar the broncho-alveolar lavage fluid and the degree of activation of cells in the lavage fluid in terms of release of fluids and airway hyperresponsiveness. 83 The targeting of other cytokines such as IL-5 is a strategy (already disoxygen free radicals, confirming the anti-inflammatory capabilities of this cytokine in vivo. Using a recombinant cussed above) which has been tested in the mouse 33 and the monkey 54 by the administration of monoclonal antiadenovirus vector to transfer IL-10 intranasally to ovalbumin-sensitized mice, Ohkawara et al 93 have shown bodies. The soluble receptors for the ␣-and ␤-chains of IL-5 (IL-5R␤) or mutant inactive forms of IL-5 remain the decreased total cell and eosinophil numbers and decreased IL-5 levels in the broncho-alveolar fluids. subject of continuing research. The use of a soluble receptor IL-5R␤ would have the advantage that it could simulTo summarize, the different biological tools which are presently envisaged in asthma in order to block the actitaneously decrease the levels of IL-3 and GM-CSF, these three cytokines possessing a common ␤-chain in the heart vation of Th2 lymphocytes or to induce anergy or switch of Th2 cells towards the Th1 phenotype are synthetic of their receptors. This hypothesis would require confirmation using an experimental model. The use of receppeptides, soluble CD40, soluble receptors (IL-4R, IL-1R, TNF) and immunomodulatory cytokines: IFN-␥, IL-10, tor antagonists for IL-1 (IL-1R) in the guinea pig 65 and of soluble receptors for TNF-␣ in the mouse 47 has, in both IL-12, TGF-␤, and Tyr-Asp-IL-4 mutant. There are indeed some promising data concerning gene therapy in animal cases, resulted in a decrease in eosinophil infiltration. In a human model of the cutaneous allergic reaction, the models of asthma and allergy. 82, 83, 93 Gene transfer techniques would not only prevent the rapid induction of an subcutaneous injection of IL-1R at the site of allergen injection in 15 allergic patients led to reduction and even immune response directed against the therapeutic proteins which would be given in a purified form, but would complete abolition of the cutaneous response. 84 In other inflammatory diseases such as rheumatoid arthritis the also avoid their rapid degradation allowing sustained levels in the airways, and the onset of systemic sideuse of p55 TNF-␣ receptors has been shown to be efficacious and is currently the subject of a clinical trial. 85 effects which they could induce if administred systemically. IL-12 is another candidate for such intervention. This cytokine is produced principally by cells of the monocyte-macrophage lineage and can direct the immune Action on transcription factors: The binding of cytokines to their membrane receptors provokes a cascade of enzyresponse towards a Th1 phenotype by favoring the pro-514 matic reactions which result in the activation of transcripthe equilibrium between the transcription factors whose activity is modulated by the corticosteroids, for example tion factors such as the AP-1 complexes (jun/fos or jun/jun) and nuclear factor-kappa B (NF-B). These two by transferring the genes of either anti-inflammatory transcription factors (such as GR mutants deleted from factors have the ability to inhibit the activation of the transcription by the GR and vice versa. 94 In the majority the ligand binding domain, which are active even in the absence of the hormone) or antagonists of pro-inflammaof cases, this mutual transrepression is mediated by a physical protein-protein interaction between the GR and tory transcription factors (such as fra-1, a member of the AP-1 protein family, which renders the fra-1-jun complex AP-1 or the GR and NF-B (Figure 4 ). In the case of the gene for proliferine, it appears that a 'composite' responinactive, or I-B, which is the natural NF-B inhibitor).
The use of such a strategy demands further evaluation sive element of corticosteroids is able to fix both to the GR and AP-1, leading to the activation or suppression of since it would be an interesting alternative to oral corticosteroids, avoiding their side-effects, which are sometimes transcription by the corticosteroids depending upon the composition of the AP-1 complex. 94 It is important to note very severe. As a first and convincing step towards this, Wrighton et al 95 have constructed a recombinant adenothat AP-1 and NF-B induce the synthesis of numerous pro-inflammatory cytokines such as TNF-␣, IL-1 and ILvirus containing the I-B␣ gene fused to a nuclear localization signal. Infection of endothelial cells with this vector 2 which can in turn activate these transcription factors. 94 It is likely that the corticosteroids break the cycle of resulted in successful reduction of expression of numerous markers of endothelial activation following lipopolyinflammation by inhibiting the AP-1 and/or NF-B transcriptional activities. Hence, in steroid-resistant asthma, saccharide stimulation, including VCAM-1, IL-1, 6, 8 and tissue factor. it follows logically that persistent inflammation is due to a functional or quantitative deregulation either in the GR or in the interacting transcription factors. In agreement with this hypothesis, Adcock et al 27 have found an
Conclusions increase in AP-1 complexes in nuclear extracts of periphAs we said in the introduction, the search for a possible eral blood lymphocytes obtained from steroid-resistant gene therapy for severe asthma may not only be a patients. Numerous possibilities for new therapeutic straresearch exercise in therapeutic strategies since data have tegies at these levels could be envisaged. Recent data in come out very recently. 82, 83, 93 Once a clear fundamental the literature suggest that a modification in the local cytomechanism underlying the disease has been described, kine microenvironment could reverse a qualitative abnorthe associated pathways could theoretically be blocked mality in the GR: the association between IL-2 and IL-4 by using genes in place of drugs. The principal strategy decreases the affinity of the GR for the corticosteroids in asthma has been to inhibit the action of Th2 lymphoand this effect can be reversed by IFN-␥. 24 The strategies cytes whose cortege of cytokines are responsible, at least which can be envisaged here include an antisense gene in part, for the pathophysiology of the disease. There therapy targeting the gene for IL-4 or a genetic immunoremain, however, numerous obstacles in our path, which modulation which would favor the Th1 phenotype over are due to the incomplete nature of our knowledge of the Th2 cells, this being achieved for example, by the propathophysiology of asthma, principally which cell type ducts of the genes for IFN-␥ and IL-12 (as already to target, the best candidate gene or side-effects of the described above). Another strategy would be to restore vectors available for gene transfer. It is also clear that even the most severe forms of asthma do not fulfill all the classical criteria for gene therapy: a potentially lethal disease, without alternative therapy in which the responsible gene(s) is or are known and completely characterized and for which the product is nontoxic. However, it might be worthwhile to carry on studies to test the feasibility of such a step. Moreover, data obtained from molecular genetic studies and from the Human Genome Program together with pathophysiological advancements may, in the near future, give rise to the discovery of genes which make the individual susceptible to asthma and thus become candidates for an even more finely targeted gene therapy. uedoc-Roussillon for their financial support.
